-

RefleXion to Present at 2024 Jefferies Global Healthcare Conference

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, Inc., a theranostic external-beam radiotherapy company, today announced that Todd Powell, president and chief executive officer, Sam Mazin, Ph.D., founder and chief technology officer, and Sean Shirvani, M.D., chief medical officer will present an overview of the company and its breakthrough SCINTIX biology-guided radiotherapy at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 8:30 a.m. EDT.

About RefleXion Medical

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors arising from either primary lung and bone cancers or resulting from metastases by other primary cancers. In addition to SCINTIX therapy, the RefleXion X1 is also FDA-cleared for conventional image-guided external-beam radiotherapy for solid tumors located anywhere in the body. For more information, please visit www.reflexion.com.

Contacts

RefleXion Contact:
Amy Cook
acook@reflexion.com
+1 925-222-5094

Industry:

RefleXion Medical, Inc.

Details
Headquarters: Hayward, CA
CEO: Todd Powell
Employees: 265
Organization: PRI
Release Versions
English
Hashtags
#CancerTreatment
#Reflexion
#SCINTIX

Contacts

RefleXion Contact:
Amy Cook
acook@reflexion.com
+1 925-222-5094

Social Media Profiles
RefleXion LinkedIn
RefleXion X
More News From RefleXion Medical, Inc.

RefleXion Medical Announces First Clinical Outcomes for SCINTIX Therapy in Lung and Bone Tumors

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, an external‑beam theranostic oncology company, today announced first results from the PREMIER Registry (NCT05406167) evaluating its SCINTIX® biology-guided radiotherapy, or BgRT, platform in patients with lung and bone tumors. The findings, presented at the 2025 ASTRO Annual Meeting, showed local control of 100 percent at nine months post-treatment with no reported Grade 2 or higher adverse events. The data represent the first prospective, mu...

RefleXion Announces Executive Appointments

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson to chief operating officer (COO). Both report to Todd Powell, RefleXion’s president and chief executive officer. “Steve’s 30-year track record of excellence and diverse background will be a tremendous asset to the RefleXion team,” said Powell. “He brings extensive experience in fundraising, financia...

RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1. “At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments,” said Arash...
Back to Newsroom